Dave Denton Steps Down as Pfizer's Chief Financial Officer

Pfizer has confirmed that Dave Denton, Executive Vice President and Chief Financial Officer, will leave the company on 15 August. He is moving to a new role in the consumer goods sector.

Cecile Guegan, Senior Vice President of Finance for the global biopharmaceutical business, will assume the Chief Financial Officer position on an interim basis from 16 August. The company is conducting an internal and external search for a permanent appointment.

Dave and Cecile will work together during the handover period to maintain continuity.

Denton's time at Pfizer

Dave oversaw the finance function during a period of major acquisitions. His tenure included oversight of transactions that reshaped the portfolio structure.

Albert Bourla, Chairman and Chief Executive Officer of Pfizer, said: "Dave has been a steady and trusted steward of Pfizer's financial health and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven and Metsera, that will serve Pfizer well for years to come.

"We wish him the very best as he returns to the consumer goods industry.

"Given Cecile's deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer's finance organisation and keep us focused on what matters most – executing our strategy and delivering for patients and shareholders."

Guegan steps into interim role

Cecile Guegan brings more than 20 years of experience at Pfizer to the interim position. She has worked across multiple divisions and therapeutic areas during her career at the company.

In her current role, she oversees financial operations and reporting for the biopharmaceutical business. This includes responsibility for all therapeutic segments and global markets.

Her previous work includes leading the financial integration of Seagen following the 2024 acquisition. Cecile holds a Master in Business degree from Brest Business School.

Dave reflects on his time at the company. He said: "It has been an honour and privilege to work alongside Albert for Pfizer, an iconic and purpose-driven company, during such a meaningful time in its history."

Finance leadership during integration

Dave adds: "Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward."

The leadership change occurs as Pfizer integrates its multi-billion dollar acquisitions into operations. The finance function will continue to focus on execution, cost management and capital deployment across the global pipeline.

Cecile will maintain oversight of these priorities while the board evaluates candidates for the permanent role. The search process will consider both internal and external options.